A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation

Clinical Transplantation

Volumn 18, Issue 3, 2004, Pages 312-320

  Tilden, Dominic P ^a   Chapman, Jeremy ^b   Davey, Peter J ^c   Solly, Michaela L ^d   Crowley, Steven ^e  

^a M TAG   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c M TAG   (Australia)

^d GLAXOSMITHKLINE   (Australia)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Cost effectiveness; Cytomegalovirus; Renal transplantation; Utility theory; Valaciclovir

Indexed keywords

ACICLOVIR; GANCICLOVIR; PLACEBO; VALACICLOVIR;

ADULT; AGED; ARTICLE; AUSTRALIA; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; GRAFT FAILURE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; KIDNEY DONOR; KIDNEY TRANSPLANTATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECIPIENT; REGISTER; SEROLOGY;

ACYCLOVIR; ANTIVIRAL AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MARKOV CHAINS; MODELS, BIOLOGICAL; MODELS, ECONOMIC; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VALINE;

EID: 2942515227     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00168.x     Document Type: Article

References (21)

1. Lowance D, Neumayer HH, Legendre CM, Squifflet JP et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999: 340: 1462.
2. Lewis RM, Johnson PC, Golden D, Van Buren CT et al. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. Transplantation 1988: 45: 353.
3. Pouteil-Noble C, Ecochard R, Landrivon G, Donia-Maged A et al. Cytomegalovirus infection - an etiological factor for rejection? Transplantation 1993: 55: 851.
4. Boland GJ, Hene RJ, Ververs C, de Haan MA et al. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993: 94: 306.
5. Emery VC, Sabin CA, Cope AV, Gor D et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000: 355: 2032.
6. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993: 55: 1277.
7. Griffiths PD, Whitley RJ (eds). The Challenge of CMV Infection and Disease in Transplantation. Recommendations from the International Herpes Management Forum (IHMF) Management Strategies Workshop and 8th Annual Meeting of the IHMF. http://www.ihmf.org/ library/monograph/m_10.pdf
8. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1381.
9. Fishman JA, Doran MT, Volpicelli SA, Cosimi AB et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000: 69: 389.
10. Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transpl 1997: 11: 633.
11. Flechner SM, Avery RK, Fisher R, Mastoianni BA et al. A randomised prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998: 66: 1682.
12. McGavin JK, Goa KJ. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001: 61: 1153.
13. Legendre CM, Norman DJ, Keating MR, Maclaine GD et al. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000: 70: 1463.
14. Mauskopf JA, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Pharmacoeconomics 2000: 18: 239.
15. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth of Australia, November 1995.
16. Mitchell SV, Smallwood RA, Angus PW, Lapsley HM. Can we afford to transplant? Med J Aust 1993: 158: 190.
17. Laupacis A, Keown P, Pus N, Krueger H et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996: 50: 235.
18. Humar A, Gillingham KJ, Payne WD, Dunn DL et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999: 68: 1879.
19. Disney APS, Russ GR, Walker R, Shiel AGR et al. (eds). ANZDATA Registry Report. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 1999.
20. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision-making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001: 19: 1103.
21. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1999.